[Interview] K.V. Subramaniam, Chief Executive Officer of Reliance Life Sciences

In this interview, K.V. Subramaniam, MBA, Chief Executive Officer of Reliance Life Sciences, discusses the history of Reliance Life Sciences and their companies evolution over their 13 year history. With K.V.'s extensive knowledge in emerging markets, he discusses what it takes to gain traction in India and other emerging markets... more specifically, he discusses the innovation imperatives for India and other emerging markets; in regards to where he sees needs, and the opportunities for technology and product solutions. On top of that, K.V. discusses how the market itself has changed over the years and what it will look like moving into 2016 and beyond.

Access the Interview 

Interested in learning more? Join us at BPI West - March 14-17 in Oakland, CA. Register before 2/19 with the code BPIWEST16BL and save $300!

Share this article with your social network, just click below to share now!

Share |

Biosimilars on the move in Asia

While the United States waits on the ruling of the healthcare act tomorrow, including the fate of Biosimilars in the US, from the Supreme Court tomorrow, many countries in Asia Pacific have are embracing the opportunity of biosimilars in their market.  Many of the countries in Asia Pacific have embraced this more cost effective form of treatment for their growing middle class, who often pays for health insurance out of their pockets.  Countries like China, India and Korea lead the way  in manufacturing and others including Japan, Australia, Singapore and Malaysia have regulations according to Pharma Phorum.  While many of these biosimilars companies have no experience in regulated markets, they are developing and distributing biosimilars to semi-regulated.  This gives them immense amounts of knowledge of the drugs, as the Asian biosimilars market accounts for 25% of the worldwide market.

This September in Boston, the Business of Biosimilars and Generic Drugs will hear from Andrew Shaw, Senior Director, PKDM, Mylan on the topic of globalizing generics and biosimilars.   It could be argued that America is an emerging market in biosimilars, and Shaw will be discussing that.  For more information on Shaw's presentation and the rest of the program, download the agenda here.  If you'd like to join us this September in Boston, register with code XP1786BLOG and save 25% off the standard rate.

What are the benefits of the companies operating in the semi-regulated markets to their business when they decide to expand in to a regulated market, such as the United States or Europe?

Share this article with your social network, just click below to share now!

Share |

Emerging markets in emerging countries growing more competitive

The United States, Europe and Japan continue to be the headquarters for Pharma companies.  The cost of hosting innovation headquarters is high, but worth the price due to the innovation and research that comes out of the areas.  However many companies are seeing the importance of expanding into regions with growing markets balancing traditional headquarters with emerging markets.  May of the countries seeing an increased interest from Pharma are Brazil, India, China, Asia and Latin America.  According to Lab Manager Magazine, these countries in emerging markets are encountering growing economies, large populations, rising personal income levels and progressive political policies.  These conditions make these countries rip for investment, manufacturing being one of the key focuses.

The need for brand name Pharma products is also fueling the growth according to David Wilton, Regional Director, Corporate Solutions for Jones Lang LaSalle in Asia Pacific.  He says “In most emerging markets, local consumers seek affordable drugs from known, trusted makers so early establishment in population-dense countries like China, India and Indonesia is vital to capture market share. Demand for drugs within these markets is increasing due to the shift in lifestyle created by the rise in personal income and purchasing power. This has resulted in a heightened awareness of traditionally Western diseases and associated treatments.”

This lends itself to the growing amount of clinical trials taking place in emerging markets.  Many companies expanding to Latin America and Asia to reach new populations of potential clinical trial participants.  The Partnerships in Clinical Trials conference series looks at many of these markets through their growing portfolio of global events - Partnerships in Clinical Trials, Partnerships in Clinical Trials Latin America and Partnerships in Clinical Trials Asia.

What are the benefits from a company expanding its resources and relocating parts/expanding of its business to emerging countries?

Share this article with your social network, just click below to share now!

Share |